Saudi Arabia to begin local production of Januvia and Janumet diabetes drugs
The Local Content Authority announces transfer of Januvia and Janumet drug manufacturing to Saudi Arabia, boosting national pharmaceutical capabilities.
Key Takeaways
AIThe Local Content and Government Procurement Authority has highlighted key achievements of its economic participation program to develop the pharmaceutical industry in Saudi Arabia, in partnership with global healthcare company MSD, aiming to strengthen research and innovation in the health sector.
The authority stated that it has successfully transferred the manufacturing technology for the diabetes medications Januvia and Janumet to the Kingdom through the Dammam Pharma factory, contributing to the localization of production for these essential treatments for diabetes patients.
The authority confirmed that the program includes training and qualifying Saudi professionals on the latest pharmaceutical manufacturing technologies, as well as enhancing supply chains and localizing the equipment required for production processes.
View the post on X
Advancing health research and development
In the same context, the authority referred to a clinical research project aimed at promoting the optimal use of antibiotics.
The project focuses on raising awareness among healthcare providers about scientific practices in prescribing antibiotics, and empowering health sector workers through technological solutions such as the Sanford platform, which helps them make accurate treatment decisions.